{
    "Rank": 927,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00125021",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "03-070"
                },
                "Organization": {
                    "OrgFullName": "Dana-Farber Cancer Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Tarceva and Capecitabine for Pancreatic Cancer",
                "OfficialTitle": "A Phase II Study of OSI-774 (Tarceva) in Combination With Capecitabine in Previously Treated Patients With Metastatic Pancreatic Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "October 2009",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "October 2003"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 2004",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "September 2008",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "July 27, 2005",
                "StudyFirstSubmitQCDate": "July 27, 2005",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "July 29, 2005",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "October 30, 2009",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "November 1, 2009",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyOldNameTitle": "Matthew Kulke, MD",
                    "ResponsiblePartyOldOrganization": "Dana-Farber Cancer Institute"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Dana-Farber Cancer Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Genentech, Inc.",
                            "CollaboratorClass": "INDUSTRY"
                        },
                        {
                            "CollaboratorName": "Roche Global Development",
                            "CollaboratorClass": "OTHER"
                        },
                        {
                            "CollaboratorName": "Brigham and Women's Hospital",
                            "CollaboratorClass": "OTHER"
                        },
                        {
                            "CollaboratorName": "Massachusetts General Hospital",
                            "CollaboratorClass": "OTHER"
                        },
                        {
                            "CollaboratorName": "Beth Israel Deaconess Medical Center",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {},
            "DescriptionModule": {
                "BriefSummary": "This phase II trial is designed to investigate the effectiveness of Tarceva (OSI-774) combined with capecitabine in treating patients with metastatic pancreatic cancer.",
                "DetailedDescription": "Patients will be treated once daily with Tarceva, twice daily with capecitabine for 14 consecutive days, followed by 7 days off of capecitabine (a cycle is 21 days). At week 1 of each cycle a physical exam and blood work will be performed. Reassessment of tumor size will be conducted at 6 weeks (2 cycles), 12 weeks (4 cycles) and then every 9 weeks thereafter. Patients will remain on treatment until one of the following occur: disease progression, illness that prevents further treatment or unacceptable adverse events."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Pancreatic Cancer",
                        "Neoplasm Metastasis"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Second Line Therapy",
                        "Gemcitabine Refractory",
                        "Pancreatic Cancer",
                        "Capecitabine",
                        "Tarceva",
                        "OSI-774",
                        "Metastatic Pancreatic Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Non-Randomized",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "32",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Capecitabine",
                            "InterventionDescription": "Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days)."
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "OSI-774",
                            "InterventionDescription": "Given once daily",
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Tarceva"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "To assess the response rate associated with capecitabine and OSI-774 in patients with advanced pancreatic cancer"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "To assess the side effects of capecitabine and OSI-774 in patients with advanced pancreatic cancer",
                            "SecondaryOutcomeTimeFrame": "2 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "to estimate the time to progression and overall survival of patients with advanced pancreatic cancer treated with capecitabine and OSI-774"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nMetastatic pancreatic carcinoma (excluding pancreatic endocrine tumors)\nOnly patients with measurable disease\nECOG performance status < or equal to 1\nLife expectancy >12 weeks\nSigned informed consent\nFailed or intolerance to first-line therapy for metastatic disease with a gemcitabine-containing regimen. Patients may have received adjuvant therapy in addition to one prior regimen for metastatic disease.\n>4 weeks must have elapsed from the completion of previous chemotherapy and patients must have recovered from any related toxicities\n>4 weeks must have elapsed from the participation in any investigational drug study\n\nLaboratory values:\n\nANC > 1500/mm3;\nHemoglobin > 9.0 gm/dl;\nPlatelets > 100,000/mm3;\nSGOT <2.5 X upper limit of normal; or <5 X upper limit of normal if evidence of liver metastases; Alkaline phosphatase < 2.5 X upper limit of normal; or < 5 X upper limit of normal if evidence of liver metastases; Total bilirubin < 1.5 X upper limit of normal; Creatinine clearance > 50 cc/min (by Cockroft - Gault or as determined from a 24-hour urine collection).\n\nExclusion Criteria:\n\nPrior therapy with capecitabine or epidermal growth factor receptor (EGFR) inhibitors\nMore than one prior chemotherapy treatment regimen for metastatic disease\nClinically apparent central nervous system (CNS) metastases or carcinomatous meningitis\nClinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication or heart attack within the last 12 months).\nMajor surgery within 4 weeks of the start of study treatment, without complete recovery.\nEvidence of CNS metastases (unless CNS metastases have been stable for > 3 months) or history of uncontrolled seizures, central nervous system disorders\nUncontrolled serious medical or psychiatric illness\nWomen must not be pregnant or lactating\nConcurrent radiation therapy\nOther active malignancy\nInability to swallow tablets\nPatients lacking physical integrity of the upper gastrointestinal tract or who have malabsorption syndrome\nPrior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Matthew Kulke, MD",
                            "OverallOfficialAffiliation": "Dana-Farber Cancer Institute",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Massachusetts General Hospital",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02114",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Beth Israel Deaconess Medical Center",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02115",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Dana-Farber Cancer Institute",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02115",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000009362",
                            "ConditionMeshTerm": "Neoplasm Metastasis"
                        },
                        {
                            "ConditionMeshId": "D000010190",
                            "ConditionMeshTerm": "Pancreatic Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009385",
                            "ConditionAncestorTerm": "Neoplastic Processes"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000010335",
                            "ConditionAncestorTerm": "Pathologic Processes"
                        },
                        {
                            "ConditionAncestorId": "D000004067",
                            "ConditionAncestorTerm": "Digestive System Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000004701",
                            "ConditionAncestorTerm": "Endocrine Gland Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000004066",
                            "ConditionAncestorTerm": "Digestive System Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000010182",
                            "ConditionAncestorTerm": "Pancreatic Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000004700",
                            "ConditionAncestorTerm": "Endocrine System Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M11997",
                            "ConditionBrowseLeafName": "Neoplasm Metastasis",
                            "ConditionBrowseLeafAsFound": "Neoplasm Metastasis",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M12800",
                            "ConditionBrowseLeafName": "Pancreatic Neoplasms",
                            "ConditionBrowseLeafAsFound": "Pancreatic Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M12020",
                            "ConditionBrowseLeafName": "Neoplastic Processes",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8576",
                            "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6946",
                            "ConditionBrowseLeafName": "Digestive System Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7553",
                            "ConditionBrowseLeafName": "Endocrine Gland Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M6945",
                            "ConditionBrowseLeafName": "Digestive System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M8573",
                            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M12792",
                            "ConditionBrowseLeafName": "Pancreatic Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M7552",
                            "ConditionBrowseLeafName": "Endocrine System Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T4387",
                            "ConditionBrowseLeafName": "Pancreatic Cancer",
                            "ConditionBrowseLeafAsFound": "Pancreatic Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC06",
                            "ConditionBrowseBranchName": "Digestive System Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC19",
                            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000069287",
                            "InterventionMeshTerm": "Capecitabine"
                        },
                        {
                            "InterventionMeshId": "D000069347",
                            "InterventionMeshTerm": "Erlotinib Hydrochloride"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000964",
                            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000000963",
                            "InterventionAncestorTerm": "Antimetabolites"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000047428",
                            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M2986",
                            "InterventionBrowseLeafName": "Gemcitabine",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M377",
                            "InterventionBrowseLeafName": "Capecitabine",
                            "InterventionBrowseLeafAsFound": "Ultrasound",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M398",
                            "InterventionBrowseLeafName": "Erlotinib Hydrochloride",
                            "InterventionBrowseLeafAsFound": "Produced",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M3971",
                            "InterventionBrowseLeafName": "Antimetabolites",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25510",
                            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}